Truist Securities handhaafde donderdag een houdadvies voor Hims & Hers Health Inc. (NYSE: HIMS) met een koersdoel van $ 45,00. De analist van Truist gaf commentaar op de implicaties van Evernorth’s re ...

Op donderdag heeft Citi-analist Daniel Grosslight zijn verkoopadvies voor aandelen van Hims and Hers Health Inc. (NYSE: HIMS) herbevestigd, met een koersdoel van $ 30,00. Volgens InvestingPro data hee ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at ...

Cigna’s Evernorth unit scored a deal with Eli Lilly and Novo Nordisk to make weight loss drugs more affordable for insured ...

Only half of health insurer Cigna’s (NYSE:CI) clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.